Merck KGaA (MRK) Given a €120.00 Price Target by UBS Group Analysts

UBS Group set a €120.00 ($142.86) price objective on Merck KGaA (FRA:MRK) in a research report sent to investors on Monday morning, www.boersen-zeitung.de reports. The brokerage currently has a buy rating on the healthcare company’s stock.

Several other brokerages have also recently issued reports on MRK. Oddo Bhf set a €125.00 ($148.81) target price on Merck KGaA and gave the stock a buy rating in a research report on Friday, November 10th. JPMorgan Chase & Co. set a €95.00 ($113.10) price objective on Merck KGaA and gave the company a neutral rating in a research report on Friday, December 29th. Morgan Stanley set a €103.00 ($122.62) price objective on Merck KGaA and gave the company a neutral rating in a research report on Monday, September 25th. Nord/LB reaffirmed a neutral rating on shares of Merck KGaA in a research report on Tuesday, January 2nd. Finally, DZ Bank reaffirmed a neutral rating on shares of Merck KGaA in a research report on Tuesday, November 14th. Twelve analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of €107.57 ($128.06).

Merck KGaA (FRA MRK) opened at €91.72 ($109.19) on Monday. The stock has a market capitalization of $11,870.00 and a PE ratio of 21.48. Merck KGaA has a 12-month low of €87.33 ($103.96) and a 12-month high of €115.00 ($136.90).

TRADEMARK VIOLATION WARNING: This article was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.dispatchtribunal.com/2018/01/12/merck-kgaa-mrk-given-a-120-00-price-target-by-ubs-group-analysts.html.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply